Published in Biochemistry on October 27, 1998
The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch (2003) 2.20
Crystal structure of a prokaryotic homologue of the mammalian oligopeptide-proton symporters, PepT1 and PepT2. EMBO J (2010) 2.05
Switching between the two action modes of the dual-affinity nitrate transporter CHL1 by phosphorylation. EMBO J (2003) 1.97
Structural basis for dynamic mechanism of proton-coupled symport by the peptide transporter POT. Proc Natl Acad Sci U S A (2013) 1.45
Crystal Structures of the Extracellular Domain from PepT1 and PepT2 Provide Novel Insights into Mammalian Peptide Transport. Structure (2015) 1.42
Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol Aspects Med (2013) 1.33
Membrane topology of human ASBT (SLC10A2) determined by dual label epitope insertion scanning mutagenesis. New evidence for seven transmembrane domains. Biochemistry (2006) 1.03
Molecular modeling of PepT1--towards a structure. J Membr Biol (2007) 1.00
Molecular insights into proton coupled peptide transport in the PTR family of oligopeptide transporters. Biochim Biophys Acta (2014) 1.00
Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. AAPS PharmSci (2000) 0.95
Genomic structure of proton-coupled oligopeptide transporter hPEPT1 and pH-sensing regulatory splice variant. AAPS PharmSci (2001) 0.94
The transmembrane tyrosines Y56, Y91 and Y167 play important roles in determining the affinity and transport rate of the rabbit proton-coupled peptide transporter PepT1. Int J Biochem Cell Biol (2009) 0.94
Mutagenesis and cysteine scanning of transmembrane domain 10 of the human dipeptide transporter. Pharm Res (2009) 0.93
The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol (2011) 0.92
Review. The mammalian proton-coupled peptide cotransporter PepT1: sitting on the transporter-channel fence? Philos Trans R Soc Lond B Biol Sci (2009) 0.91
Site-directed mutagenesis of Arginine282 suggests how protons and peptides are co-transported by rabbit PepT1. Int J Biochem Cell Biol (2007) 0.89
Evidence that the rabbit proton-peptide co-transporter PepT1 is a multimer when expressed in Xenopus laevis oocytes. Pflugers Arch (2006) 0.86
Bioavailability through PepT1: the role of computer modelling in intelligent drug design. Curr Comput Aided Drug Des (2010) 0.83
Peptide transporter DtpA has two alternate conformations, one of which is promoted by inhibitor binding. Proc Natl Acad Sci U S A (2013) 0.82
Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.81
New tags for recombinant protein detection and O-glycosylation reporters. PLoS One (2014) 0.80
Functional role of the intracellular loop linking transmembrane domains 6 and 7 of the human dipeptide transporter hPEPT1. J Membr Biol (2010) 0.78
Identification of Extracellular Segments by Mass Spectrometry Improves Topology Prediction of Transmembrane Proteins. Sci Rep (2017) 0.75
Drug inhibition of Gly-Sar uptake and hPepT1 localization using hPepT1-GFP fusion protein. AAPS PharmSci (2001) 0.75
Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci (2000) 2.63
The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res (1997) 2.28
Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm (2000) 2.14
Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res (1998) 2.08
Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res (1996) 2.05
Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem (1995) 1.93
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
Hydrophobic amino acid in the i2 loop plays a key role in receptor-G protein coupling. J Biol Chem (1993) 1.64
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther (1997) 1.64
Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem (2001) 1.53
Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci (2000) 1.45
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci (2004) 1.41
Targeted prodrug design to optimize drug delivery. AAPS PharmSci (2000) 1.36
A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm (1999) 1.35
Allelic expression of serotonin transporter (SERT) mRNA in human pons: lack of correlation with the polymorphism SERTLPR. Mol Psychiatry (2006) 1.27
Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J Pharmacol Exp Ther (1996) 1.26
Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. Cancer Chemother Rep (1975) 1.24
Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology (1988) 1.23
[Spectrophotometric determination of 5-phenyl-1,4-benzodiazepine-derivatives and studies on metabolism of nitrazepam. 5. Chemistry and analytics of benzodiazepine-derivatives]. Arzneimittelforschung (1969) 1.22
Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res (1985) 1.22
Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci (1985) 1.21
Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci (1994) 1.20
The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm (1987) 1.20
Moisture sorption kinetics for water-soluble substances. I: Theoretical considerations of heat transport control. J Pharm Sci (1983) 1.19
Determination of metronidazole and misonidazole and their metabolites in plasma and urine by high-performance liquid chromatography. J Chromatogr (1978) 1.18
Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev (1996) 1.17
Prediction of physical aging in controlled-release coatings: the application of the relaxation coupling model to glassy cellulose acetate. Pharm Res (1991) 1.14
Influence of physical aging on mechanical properties of polymer free films: the prediction of long-term aging effects on the water permeability and dissolution rate of polymer film-coated tablets. Pharm Res (1991) 1.13
Sequestration of dopamine D2 receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5. Eur J Biochem (1999) 1.12
Scaleup of immediate release oral solid dosage forms. Pharm Res (1993) 1.10
G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity. Biochem J (2000) 1.10
Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res (2000) 1.09
Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure. Eur J Clin Pharmacol (1974) 1.08
Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure. J Infect Dis (1973) 1.08
Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res (1998) 1.07
Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). J Pharm Sci (2006) 1.07
Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem (2001) 1.06
Regulation of cyclic AMP by the mu-opioid receptor in human neuroblastoma SH-SY5Y cells. J Neurochem (1990) 1.06
An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res (1998) 1.05
Calmodulin binding to G protein-coupling domain of opioid receptors. J Biol Chem (1999) 1.05
Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther (1973) 1.05
HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci (1996) 1.05
Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther (1982) 1.04
Hm1 muscarinic cholinergic receptor internalization requires a domain in the third cytoplasmic loop. J Biol Chem (1992) 1.03
Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci (1996) 1.03
A constitutively internalizing and recycling mutant of the mu-opioid receptor. J Neurochem (1997) 1.02
Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res (1993) 1.02
Biology of membrane transport proteins. Pharm Res (1995) 1.02
Protein denaturation during freezing and thawing in phosphate buffer systems: monomeric and tetrameric beta-galactosidase. Arch Biochem Biophys (2000) 1.02
Efficacy and tolerance of narcotic analgesics at the mu opioid receptor in differentiated human neuroblastoma cells. J Pharmacol Exp Ther (1988) 1.01
Evolutionary relationships among proteins probed by an iterative neighborhood cluster analysis (INCA). Alignment of bacteriorhodopsins with the yeast sequence YRO2. Pharm Res (1997) 1.00
Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. Clin Pharmacol Ther (2011) 1.00
Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J Control Release (1999) 0.98
In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine. Gene Ther (1998) 0.98
Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res (1991) 0.98
Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane. Biochemistry (1998) 0.98
Evolutionary relationships among G protein-coupled receptors using a clustered database approach. AAPS PharmSci (2001) 0.98
Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Hum Gene Ther (1998) 0.98
A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem (2000) 0.98
Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res (2001) 0.98
Solubility of nonelectrolytes in polar solvents II: solubility of aliphatic alcohols in water. J Pharm Sci (1974) 0.97
Solubility of nonelectrolytes in polar solvents IV: nonpolar drugs in mixed solvents. J Pharm Sci (1976) 0.96
Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn (2001) 0.95
Serine- and threonine-rich domain regulates internalization of muscarinic cholinergic receptors. J Biol Chem (1993) 0.95
Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci (2000) 0.95
Compartmentation of guanine nucleotide precursors for DNA synthesis. Biochem J (1986) 0.95
Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach. J Theor Biol (1988) 0.95
Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. AAPS PharmSci (2000) 0.95
Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res (1990) 0.94
Genomic structure of proton-coupled oligopeptide transporter hPEPT1 and pH-sensing regulatory splice variant. AAPS PharmSci (2001) 0.94
Viscoelastic properties of polyacrylic acid gels in mixed solvents. Pharm Res (1992) 0.94
Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J Pharmacol Exp Ther (2001) 0.93
In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method. Eur J Pharmacol (1985) 0.93
Expression of neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma cell line. Cancer Res (1987) 0.93
Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res (1988) 0.93
Human membrane transporter database: a Web-accessible relational database for drug transport studies and pharmacogenomics. AAPS PharmSci (2000) 0.93
Morphine persistence in rat brain and serum after single doses. J Pharmacol Exp Ther (1979) 0.93
Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm Res (1992) 0.93
Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci (1987) 0.93
Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm (1998) 0.93
Activating and inactivating mutations in N- and C-terminal i3 loop junctions of muscarinic acetylcholine Hm1 receptors. J Biol Chem (1995) 0.93
Analysis of models for determining intestinal wall permeabilities. J Pharm Sci (1980) 0.92
Scaleup of oral extended-release dosage forms. Pharm Res (1993) 0.92
Activation of a GTP-binding protein and a GTP-binding-protein-coupled receptor kinase (beta-adrenergic-receptor kinase-1) by a muscarinic receptor m2 mutant lacking phosphorylation sites. Eur J Biochem (1994) 0.92
A human neuroblastoma cell line expresses mu and delta opioid receptor sites. J Biol Chem (1986) 0.92
Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. J Pharm Sci (1989) 0.92
Incorporation of nucleotide tracers into nucleic acids in permeabilized cells and cellular homogenates. Biochem J (1986) 0.92
Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci (1988) 0.92
Characterization of the oral absorption of beta-lactam antibiotics. II. Competitive absorption and peptide carrier specificity. J Pharm Sci (1989) 0.92
Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci (1986) 0.92
Guanine ribonucleotide depletion in mammalian cells. A target of purine antimetabolites. Cancer Chemother Pharmacol (1983) 0.91
Calculation of the aqueous diffusion layer resistance for absorption in a tube: application to intestinal membrane permeability determination. Pharm Res (1991) 0.91
Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci (1982) 0.90
Sequence alignments of the H(+)-dependent oligopeptide transporter family PTR: inferences on structure and function of the intestinal PET1 transporter. Pharm Res (1997) 0.90
Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm Res (1998) 0.90
Nuclear Ca2+/calmodulin translocation activated by mu-opioid (OP3) receptor. J Neurochem (2000) 0.90
Modulated drug release using iontophoresis through heterogeneous cation-exchange membranes. 2. Influence of cation-exchanger content on membrane resistance and characteristic times. J Pharm Sci (1994) 0.90